Ascletis Pharma Inc.: Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor ...

Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The ...
The Pharma Letter

Almirall’s Seysara wins Chinese approval in acne

Spanish dermatology specialist Almirall has announced that China’s National Medical Products Administration (NMPA) has ...

Sagimet down as Chinese partner posts late-stage trial data for acne therapy

Sagimet Biosciences (SGMT) stock dips as Chinese partner Ascletis (ASCLF) reports Phase 3 trial data for the U.S. firm's acne ...

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study (NCT06248008) evaluating denifanstat (ASC40), a first-in-class, once-daily ...

Almirall Announces the Approval of Seysara® in China for the Treatment of Moderate-to-Severe Acne

Almirall, S.A. (ALM) a global pharmaceutical company dedicated to medical dermatology announced today that China’s National Medical Products Administration (NMPA) has approved Seysara® (sarecycline ...